Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.

Mol Cancer

Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.

Published: March 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018920PMC
http://dx.doi.org/10.1186/s12943-023-01754-6DOI Listing

Publication Analysis

Top Keywords

correction development
4
development 4-aminopyrazolo[34-d]pyrimidine-based
4
4-aminopyrazolo[34-d]pyrimidine-based dual
4
dual igf1r/src
4
igf1r/src inhibitor
4
inhibitor novel
4
novel anticancer
4
anticancer agent
4
agent minimal
4
minimal toxicity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!